Company · Private

Minovia Therapeutics

Cell therapy company whose Mitochondrial Augmentation Technology enriches a patient's own hematopoietic stem cells with healthy mitochondria; lead programme MNV-201 is in development for myelodysplastic syndrome and mitochondrial disease.

Listing

Private

Ticker

—

Headquarters

Haifa, Israel

Founded

—

Technology

Mitochondrial augmentation (cell therapy)

Longevity thesis

If mitochondrial dysfunction is a root feature of blood and tissue aging, augmenting stem cells with functional mitochondria could restore tissue-level energy capacity.

Programmes

MNV-201Phase 2
Myelodysplastic syndrome; mitochondrial disease

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.